arlutz73 A New Jersey federal court sided with Bristol Myers Squibb ( NYSE: BMY ) in a case brought by health insurers that the drugmaker tried to squelch generic competition for its cancer drugs Revlimid and Thalomid. Judge Esther Salas ruled on June 6 that insurers and MSP Recovery Claims Series LLC did not demonstrate that Celgene, now a part of Bristol, had monopoly power and used it to prevent generic entry, Bloomberg Law reported. Plaintiffs included Cigna ( CI ), Humana ( HUM ), and Blue Cross Blue Shield Association and Cigna Corporation.
They had argued that Bristol signed an agreement to delay a generic version of Revlimid as well as gained Revlimid patents fraudulently. More on Bristol Myers Squibb Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.84% Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss Bristol Myers Squibb: 5.
5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Bristol Myers Squibb inks clinical trial pact with I-Mab Bristol's Opdivo + Yervoy bests Lenvima, Nexavar in first-line liver cancer.
